Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...

scPharmaceuticals reported a net loss of $18.8 million for the fourth quarter of 2024, compared to $13.8 million for the fourth quarter of 2023. For the full-year 2024, scPharmaceuticals reported a ...

The US Food and Drug Administration (FDA) has broadened the approval of Furoscix (furosemide injection) to treat edema in ...

Management anticipates the Medicare redesign to positively impact FUROSCIX adoption. The redesign reduces patient out-of-pocket costs, which is expected to increase fill rates and demand.

the ongoing commercialization and marketing of FUROSCIX, and the potential label expansion and other regulatory approvals of FUROSCIX. The words anticipate, believe, estimate, expect, intend ...

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

scPharmaceuticals Inc (NASDAQ:SCPH) reported a significant increase in net revenue for FUROSCIX, with a 167% year-over-year growth, reaching $36.3 million for the full year 2024. The company ...

We will then open the line for questions. Overall, although we're satisfied with the FUROSCIX commercial growth over the course of 2024, we were especially encouraged by what we saw in Q4 ...

scPharmaceuticals reported Q4 2024 revenue of $12.2 million, FDA approved FUROSCIX for chronic kidney disease, and a net loss of $18.8 million. FUROSCIX is indicated for treating edema in patients ...